TrialClinical rheumatology2022

Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.

Jia Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.